COPD Clinical Trial
Official title:
The Long-term Effects of a Tele Coaching Intervention in Patients With COPD: a Randomized Controlled Trial
Verified date | January 2024 |
Source | KU Leuven |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality and morbidity around the world. Studies revealed that patients with COPD are less active than age-matched healthy controls and activity level decreases with disease severity. Higher levels of physical activity is related to important health-related outcomes, such as lower mortality rate and hospital admissions. Additionally, increasing physical activity is related with substantial health benefits. Patients with COPD have a higher risk of developing insulin resistance, hypertension, dyslipidemia, osteopenia, leading to chronic diseases such as coronary heart disease, type 2 diabetes and osteoporosis, which have been related to physical inactivity in the healthy population. Moreover, physical inactivity has been related to the occurrence of comorbidities in patients with COPD. Therefore, improving physical activity levels is a recommended treatment in the disease management in all patients with COPD and is implemented in the recent GOLD guidelines for all patients with COPD, regardless of the disease severity. The research group investigated the effect of a 3-month semi-automatic tele-coaching intervention on physical activity levels in patients with COPD. The tele coaching intervention led to a significant improvement on physical activity in the intervention group. Although this trial showed positive results on physical activity, further research is needed, mainly to investigate the long-term (12 months) effectiveness of such interventions and the added value of a smartphone application on top of a simple step counter providing feedback. Additionally, since physical activity is related to the development of comorbidities, the investigators aim to explore the influence of improving physical activity levels on the occurrence of cardiovascular, metabolic and musculoskeletal comorbidities. Finally, this study will explore baseline characteristics (such as social support, self-efficacy, dynamic hyperinflation, etc.) that can predict success in this intervention.
Status | Completed |
Enrollment | 150 |
Est. completion date | December 11, 2023 |
Est. primary completion date | December 11, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: 1. Patients diagnosed with COPD (GOLD criteria post bronchodilator FEV1/FVC < 0.70) 2. Patients under medical follow-up of a respiratory physician or general practitioner with no moderate (ambulatory treated) and/or severe (requiring a hospital admission) exacerbation in the past month 3. Older than 40 years old 4. Smoking history with more than 10 pack years Exclusion Criteria: 1. The presence of orthopedic or other problems not allowing an increase in physical activity levels 2. Unable to learn to work with a new electronic device (e.g. smartphone), as judged by the investigator 3. Underwent lung transplantation or active on the lung transplantation list 4. Involved in or planned to start with a structured multidisciplinary rehabilitation program |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Gent | Ghent | |
Belgium | UZ Leuven | Leuven |
Lead Sponsor | Collaborator |
---|---|
KU Leuven | University Ghent |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Daily number of steps at 12 months | Change in daily mean step count 12 months post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in patients with COPD. At least 4 valid weekdays (> 8 hours of wearing time during waking hours) is necessary to label the physical activity measurement as valid. | 12 months | |
Secondary | Daily number of steps at 6 months | Change in daily mean step count 6 months post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in patients with COPD. At least 4 valid weekdays (> 8 hours of wearing time during waking hours) is necessary to label the physical activity measurement as valid. | 6 months | |
Secondary | Minutes per day spent in at least moderate intense activities | Change in minutes per day spent in at least moderate intense activities 6 and 12 months post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in patients with COPD. At least 4 valid weekdays (> 8 hours of wearing time during waking hours) is necessary to label the physical activity measurement as valid. | 6 months and 12 months | |
Secondary | Mean walking time per day | Change in mean daily walking time 6 and 12 months post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in patients with COPD. At least 4 valid weekdays (> 8 hours of wearing time during waking hours) is necessary to label the physical activity measurement as valid. | 6 months and 12 months | |
Secondary | Mean sedentary time per day | Change in mean sedentary time 6 and 12 months post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in patients with COPD. At least 4 valid weekdays (> 8 hours of wearing time during waking hours) is necessary to label the physical activity measurement as valid. | 6 months and 12 months | |
Secondary | Exercise capacity | Change in six-minutes walk distance 6 and 12 months post randomization in the intervention group as compared to the control group. The six-minutes walk test will be performed with standardized encouragement to assess patients' functional exercise capacity. The best of two measurements will be used. | 6 months and 12 months | |
Secondary | Quadriceps force | Change in quadriceps force 6 and 12 months post randomization in the intervention group as compared to the control group. The quadriceps isometric strength will be evaluated by a maximal voluntary contraction using the Biodex, a computerized dynamometer. Patients will be seated with a 90° hip and 60° knee flexion. The best of 4 measurements will be taken into analysis as the maximal force capacity of the lower limb. | 6 months and 12 months | |
Secondary | Health status | Change in health status 6 and 12 months post randomization in the intervention group as compared to the control group. Health status will be measured by COPD assessment test (CAT), a validated, 8-item questionnaire to assess the impact of the disease on a patient's health status. Scores range from 0 to 40, with a higher score indicating a worse health status. The minimal clinical important difference (MCID) is a change of 3 points. | 6 and 12 months | |
Secondary | Health related quality of life: CRDQ-SAS | Change in health related quality of life 6 and 12 months post randomization in the intervention group as compared to the control group. Health status will be measured by Chronic Respiratory Disease Questionnaire; self-administrated standardized version (CRDQ-SAS), measuring both physical and emotional aspects of chronic respiratory disease. The questionnaire contains 20 items, spread over 4 domains (dyspnea, fatigue, emotional function and mastery). The minimal clinical important difference is reflected by a change in score of 0.5 on a 7-point scale. | 6 months and 12 months | |
Secondary | Physical activity from a patients' perspective | Change in physical activity from a patients' perspective 6 and 12 months post randomization in the intervention group as compared to the control group. This will be measured by PROactive tool (clinical visit version), a validated 12-item questionnaire assessing physical activity from a patient's perspective reflecting the past 7 days. The questionnaire investigates the amount of and difficulty with physical activity as perceived by the patient. The 2 domain scores (i.e. amount and difficulty) as well as the total score will be retrieved as outcomes. Subscores and total score are from 0 to 100, with higher score meaning less problems with daily life activities as reported by the patient. | 6 months and 12 months | |
Secondary | Dyspnea-related fear | Change in dyspnea-related fear 6 and 12 months post randomization in the intervention group as compared to the control group. This will be measured by breathlessness beliefs questionnaire (BBQ), an 17-item questionnaire investigating the dyspnea-related anxiety in patients with respiratory diseases. Score ranges from 17 to 85. Higher values indicate worse dyspnea-related fear. | 6 months and 12 months | |
Secondary | Symptoms of anxiety and depression | Change in symptoms of anxiety and depression 12 months post randomization in the intervention group as compared to the control group. Symptoms of anxiety and depression will be measured by the Hospital Anxiety and Depression Scale (HADs). The HADs is a generic screening measure of symptoms of anxiety and depression. The HADS is a 14 item measure comprising 7 anxiety items and 7 depression items from which separate anxiety and depression sub-scale scores are calculated, ranging from 0 to 21 for both sub domains. A score of 8 or higher indicates a high possibility of anxiety / depression | 12 months | |
Secondary | Functional performance | To investigate the effect of an acute COPD exacerbation on functional performance, functional performance will be measured by the Short physical performance battery (SPPB), timed up and go test (TUG) and 1-minute sit-to-stand (1' STS) as soon as possible (and maximally 14 days) after onset of an exacerbation. | Only in Ghent - as soon as possible and max 14 days after the occurrence of an COPD exacerbation | |
Secondary | Autonomic function | Exploring the association between change in physical activity and autonomic function. To evaluate the autonommic fuction, the patient will wear a Polar chest band with corresponding watch for 7 consecutive days (day and night). Based on this measurement we will retrieve measures on: respiratory rate; resting heart rate (heart rate during the night); heart rate variability. Data will be processed using Kubios software.
The Polar chest band with corresponding watch will also be worn while performing the 6-minute walking test as measures of HRV during exercise and heart rate recovery (HRR). Data will be processed using Kubios software. |
Only in Ghent - 6 months and 12 months; additionally at 18 months and 24 months in case of extended design | |
Secondary | Autonomic symptoms | Exploring the association between change in physical activity and autonomic fuction, To evaluate autonomic symptoms, autonomic symptoms will be measured by the COMPASS 31 questionnaire. This questionnaire contains six domains: orthostatic intolerance, vasomotor, secrotomotor, gastrointestinal, urinary and pupillomotor function. Total score ranges from 0 to 100, with higher score indicating more autonomic dysfunction. | Only in Ghent - 6 months and 12 months; additionally at 18 months and 24 months in case of extended design |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06000696 -
Healthy at Home Pilot
|
||
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04105075 -
COPD in Obese Patients
|
||
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Active, not recruiting |
NCT04075331 -
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
|
Phase 2/Phase 3 | |
Terminated |
NCT03640260 -
Respiratory Regulation With Biofeedback in COPD
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|
||
Withdrawn |
NCT04210050 -
Sleep Ventilation for Patients With Advanced Hypercapnic COPD
|
N/A | |
Terminated |
NCT03284203 -
Feasibility of At-Home Handheld Spirometry
|
N/A | |
Recruiting |
NCT06110403 -
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06040424 -
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
Completed |
NCT04485741 -
Strados System at Center of Excellence
|
||
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A |